It's been a topic of rabid internet speculation in recent days. The health of Donald Trump was once again called into question after eagle-eyed viewers caught sight of a vivid red rash on his neck.
Portela told the Daily Beast that the redness and flakiness of the nasty rash are “characteristic” of a chemotherapy cream ...
U.S. President Donald Trump appeared at the White House this week with a noticeable rash on the right side of his neck, ...
Leading dermatologists have suggested President Trump may be suffering from actinic keratosis, an unsightly skin condition ...
Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L ...
The FDA granted full approval encorafenib (Braftovi) in combination with cetuximab (Erbitux) and fluorouracil-based ...
Pfizer (NYSE:PFE) received full FDA approval for BRAFTOVI (encorafenib) with cetuximab and fluorouracil-based chemotherapy as ...
Pfizer Inc. (NYSE: PFE) is one of the most undervalued stocks under $30 to buy. On February 24, the US FDA granted full ...
The FDA has approved the first combination, targeted regimen for previously untreated BRAF V600E mutation-positive metastatic colorectal cancer.Encorafenib (Braftovi, Pfizer) plus cetuximab (Erbitux, ...
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...
Traditional approval of encorafenib plus cetuximab and fluorouracil-based chemotherapy for patients with BRAF-mutated ...
Pfizer stock rises after FDA fully approves Braftovi combo for metastatic colorectal cancer with BRAF V600E mutation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results